The
stability of the core can significantly impact the
therapeutic
effectiveness of liposome-based drugs. While the spherical nucleic
acid (SNA) architecture has elevated liposomal stability to increase
therapeutic efficacy, the chemistry used to anchor the DNA to the
liposome core is an underexplored design parameter with a potentially
widespread biological impact. Herein, we explore the impact of SNA
anchoring chemistry on immunotherapeutic function by systematically
studying the importance of hydrophobic dodecane anchoring groups in
attaching DNA strands to the liposome core. By deliberately modulating
the size of the oligomer that defines the anchor, a library of structures
has been established. These structures, combined with in vitro and in vivo immune stimulation analyses, elucidate
the relationships between and importance of anchoring strength and
dissociation of DNA from the SNA shell on its biological properties.
Importantly, the most stable dodecane anchor, (C12)9, is
superior to the n = 4–8 and 10 structures
and quadruples immune stimulation compared to conventional cholesterol-anchored
SNAs. When the OVA1 peptide antigen is encapsulated by the (C12)9 SNA and used as a therapeutic vaccine in an E.G7-OVA tumor
model, 50% of the mice survived the initial tumor, and all of those
survived tumor rechallenge. Importantly, the strong innate immune
stimulation does not cause a cytokine storm compared to linear immunostimulatory
DNA. Moreover, a (C12)9 SNA that encapsulates a peptide
targeting SARS-CoV-2 generates a robust T cell response; T cells raised
from SNA treatment kill >40% of target cells pulsed with the same
peptide and ca. 45% of target cells expressing the
entire spike protein. This work highlights the importance of using
anchor chemistry to elevate SNA stability to achieve more potent and
safer immunotherapeutics in the context of both cancer and infectious
disease.